BG
MYGN icon

BlackRock Group’s Myriad Genetics MYGN Stock Holding History

BlackRock Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.53M Buy
91,698
+4,883
+6% +$88.3K ﹤0.01% 1931
2016
Q3 		$1.79M Buy
86,815
+13,567
+19% +$344K ﹤0.01% 1698
2016
Q2 		$2.24M Sell
73,248
-212
-0.3% -$7.37K ﹤0.01% 1490
2016
Q1 		$2.75M Buy
73,460
+27,868
+61% +$1.05M ﹤0.01% 1350
2015
Q4 		$1.97M Sell
45,592
-1,307
-3% -$55.2K ﹤0.01% 1491
2015
Q3 		$1.76M Buy
46,899
+7,999
+21% +$284K ﹤0.01% 1576
2015
Q2 		$1.32M Sell
38,900
-8,683
-18% -$295K ﹤0.01% 1788
2015
Q1 		$1.69M Sell
47,583
-662
-1% -$23.7K ﹤0.01% 1561
2014
Q4 		$1.64M Buy
48,245
+4,619
+11% +$164K ﹤0.01% 1589
2014
Q3 		$1.68M Sell
43,626
-15,755
-27% -$588K ﹤0.01% 1502
2014
Q2 		$2.31M Sell
59,381
-221,273
-79% -$8.23M ﹤0.01% 1398
2014
Q1 		$9.6M Buy
280,654
+43,154
+18% +$1.34M 0.01% 933
2013
Q4 		$4.98M Buy
237,500
+6,223
+3% +$157K ﹤0.01% 1084
2013
Q3 		$5.43M Buy
231,277
+57,836
+33% +$1.64M ﹤0.01% 1045
2013
Q2 		$4.66M Buy
+173,441
New +$5.03M ﹤0.01% 1012

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock Group's MYGN Position: Q4 2016 in Review

BlackRock Group increased its Myriad Genetics (MYGN) stake by 5.6% in Q4 2016, buying an estimated $88.3K and bringing the position to 91,698 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

BlackRock Group first reported a position in MYGN in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.6M in Q1 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • BlackRock Group held 91,698 shares of Myriad Genetics worth $1.53M as of Q4 2016.
  • BlackRock Group bought 4,883 Myriad Genetics shares in Q4 2016, an estimated $88.3K.
  • Myriad Genetics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1931 holding.
  • BlackRock Group first reported a position in Myriad Genetics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Myriad Genetics position peaked at $9.6M in Q1 2014.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.